R&G PharmaStudies Co., Ltd. (SHE:301333)

China flag China · Delayed Price · Currency is CNY
66.19
-0.09 (-0.14%)
Mar 6, 2026, 4:00 PM EST
26.39%
Market Cap 6.18B
Revenue (ttm) 789.45M
Net Income (ttm) 151.37M
Shares Out 95.14M
EPS (ttm) 1.59
PE Ratio 40.84
Forward PE 44.51
Dividend 0.16 (0.24%)
Ex-Dividend Date Jul 8, 2025
Volume 2,008,340
Average Volume 2,151,595
Open 66.21
Previous Close 66.28
Day's Range 65.00 - 68.50
52-Week Range 40.99 - 91.78
Beta 0.71
RSI 38.86
Earnings Date Mar 28, 2026

About R&G PharmaStudies

R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It provides drug clinical research and development integrated services. The company’s services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology services. It serves pharmaceutical and medical device companies, and scientific research institutions. The company was founded in 2008 and is headquart... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 2,208
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 301333
Full Company Profile

Financial Performance

In 2024, R&G PharmaStudies's revenue was 744.00 million, an increase of 3.14% compared to the previous year's 721.37 million. Earnings were 140.22 million, a decrease of -13.73%.

Financial Statements

News

There is no news available yet.